Certara to Expand its Drug Discovery Software Capabilities Through the Acquisition of Chemaxon


Certara has entered into a definitive agreement to acquire Chemaxon, the financial details of which were undisclosed. The transaction is anticipated to conclude in H2’24, contingent upon regulatory approval and other customary closing conditions
The acquisition will enhance Certara’s drug discovery capabilities by incorporating Chemaxon’s software which digitizes the design, make, test & analyze (DMTA) lifecycle for the discovery of chemical leads and further allows chemical structure drawing, property prediction & analysis
The resulting entity will provide a complete data and predictive analytics platform, enhancing decision-making in drug development

Ref: Certara | Image: Certara

Related News:- Aurigene and Vipergen Enter into a Strategic Collaboration to Offer DEL Screening and Integrated Drug Discovery Services

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com